REPH Recro Pharma, Inc.

0  -1%
Previous Close 8.14
Open 8.15
Price To book 2.16
Market Cap 152.97M
Shares 19,050,000
Volume 37,062
Short Ratio 3.48
Av. Daily Volume 118,653

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from second trial released November 28, 2016. Primary endpoint met. Safety study to be completed by 1H 2017, with an NDA filing due summer 2017.
Intravenous (IV) meloxicam
Acute pain following bunionectomy surgery